Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 362-372

  Bermejo, Justo Lorenzo ^a   Kabisch, Maria ^b   Dünnebier, Thomas ^b   Schnaidt, Sven ^a   Melchior, Frauke ^c   Fischer, Hans Peter ^d   Harth, Volker ^e,f,g   Rabstein, Sylvia ^e   Pesch, Beate ^e   Brüning, Thomas ^e   Justenhoven, Christina ^h   Brauch, Hiltrud ^h,i   Baisch, Christian ^j   Ko, Yon Dschun ^j   Hamann, Ute ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GERMAN CANCER RESEARCH CENTER   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j Johanniter Krankenhaus   (Germany)

more..

Author keywords

breast cancer risk; expression; SUMOylation; tumor grade; USPL1

Indexed keywords

CYSTEINE PROTEINASE; SUMO ISOPEPTIDASE; SUMO PROTEIN; UBIQUITIN SPECIFIC PEPTIDASE LIKE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BREAST; BREAST CANCER; CANCER GRADING; CARCINOGENESIS; CONJUGATION; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENE; GENETIC DATABASE; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HAPLOTYPE MAP; HOMOZYGOTE; HUMAN; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; USPL1 GENE;

ALLELES; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DATABASES, GENETIC; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; REGRESSION ANALYSIS; SEQUENCE ANALYSIS, DNA; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TIME FACTORS;

EID: 84877827728     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28040     Document Type: Article

References (49)

1. Geiss-Friedlander R, Melchior F,. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007; 8: 947-56.
2. Gareau JR, Lima CD,. The SUMO pathway: emerging mechanisms that shape specifity, conjugation and recognition. Nat Rev Mol Cell Biol 2010; 12: 861-71.
3. Johnson ES,. Protein modification by SUMO. Annu Rev Biochem 2004; 73: 355-82.
4. Hay RT,. SUMO-specific proteases: a twist in the tail. Trends Cell Biol 2007; 17: 370-6.
5. Bawa-Khalfe T, Yeh ET,. SUMO losing balance: SUMO.proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 2010; 1: 748-752.
6. Shin EJ, Shin HM, Nam E, et al. DeSUMOylating isopeptidase: a second class of SUMO protease. EMBO Rep 2012; 13: 339-46.
7. Schulz S, Chachami G, Kozaczkiewicz L, et al. Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMBO Rep 2012; 13: 930-8.
8. Wang L, Banerjee S,. Differential PIAS3 expression in human malignancy. Oncol Rep 2004; 11: 1319-24.
9. Wu F, Zhu S, Ding Y, et al. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 2009; 15: 1550-7.
10. Mo YY, Yu Y, Theodosiou E, et al. A role for Ubc9 in tumorigenesis. Oncogene 2005; 24: 2677-83.
11. Synowiec E, Krupa R, Morawiec Z, et al. Efficacy of DNA double-strand breaks repair in breast cancer is decreased in carriers of the variant allele of the UBC9 gene c.73G>A polymorphism. Mutat Res 2010; 694: 31-8.
12. Dunnebier T, Bermejo JL, Haas S, et al. Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int J Cancer 2009; 125: 596-602.
13. Dunnebier T, Bermejo JL, Haas S, et al. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk. Breast Cancer Res Treat 2010; 121: 185-94.
14. Cheng J, Bawa T, Lee P, et al. Role of desumoylation in the development of prostate cancer. Neoplasia 2006; 8: 667-76.
15. Jacques C, Baris O, Prunier-Mirebeau D, et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 2005; 90: 2314-20.
16. Cheng J, Wang D, Wang Z, et al. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone acetylase 1. Mol Cell Biol 2004; 24: 6021-28.
17. Lee JS, Thorgeirsson SS,. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004; 127: S51-S55.
18. Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012; 335: 348-53.
19. Bossis G, Malnou CE, Farras R, et al. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 2005; 25: 6964-79.
20. Eladad S, Ye TZ, Hu P, et al. Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum Mol Genet 2005; 14: 1351-65.
21. Gostissa M, Hengstermann A, Fogal V, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999; 18: 6462-71.
22. Kawabe Y, Seki M, Seki T, et al. Covalent modification of the Werner's syndrome gene product with the ubiquitin-related protein, SUMO-1. J Biol Chem 2000; 275: 20963-6.
23. Muller S, Matunis MJ, Dejean A,. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17: 61-70.
24. Muller S, Berger M, Lehembre F, et al. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 2000; 275: 13321-9.
25. Rodriguez MS, Desterro JM, Lain S, et al. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999; 18: 6455-61.
26. Xirodimas DP, Chisholm J, Desterro JM, et al. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002; 528: 207-11.
27. Karamouzis MV, Konstantinopoulos PA, Badra FA, et al. SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat 2008; 107: 195-210.
28. Ali S, Coombes RC,. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 2000; 5: 271-81.
29. Wu H, Sun L, Zhang Y, et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem 2006; 281: 21848-56.
30. Kotaja N, Karvonen U, Janne OA, et al. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 2002; 277: 30283-8.
31. Chauchereau A, Amazit L, Quesne M, et al. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 2003; 278: 12335-43.
32. Justenhoven C, Pierl CB, Haas S, et al. The CYP1B1-1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 2008; 111: 171-7.
33. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005; 20: 699-711.
34. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61.
35. Del Val C, Pelz O, Glatting KH, et al. PromoterSweep: a tool for identification of transcription factor binding sites. Theoretical Chemistry Accounts 2010; 3-6: 583-91.
36. Marchini J, Howie B, Myers S, et al. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906-13.
37. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-73.
38. Price AL, Patterson NJ, Plenge RM, et al. Principal component analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-9.
39. Weir BS, Cockerham C,. Estimating F-Statistics for the Analysis of Population Structure. Evolution 1984; 38: 1358-70.
40. The International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52-58.
41. Excoffier L, Slatkin M,. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-27.
42. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association of traits with haplotypes when linkage phase is ambiguous. Amer J Hum Genet 2002; 70: 425-34.
43. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
44. Stranger BE, Forrest MS, Dunning M, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007; 315: 848-853.
45. Nothnagel M, Herrmann A, Wolf A, et al. Technology-specific error signatures in the 1000 Genomes Project data. Hum Genet 2011; 130: 505-16.
46. Jostins L, Morley KI, Barrett JC,. Imputation of low-frequency variants using the HapMap3 benefits from large, diverse reference sets. Eur J Hum Genet 2011; 19: 662-6.
47. Amsterdam A, Nissen RM, Sun Z, et al. Identification of 315 genes essential for early zebrafish development. Proc Natl Acad Sci USA 2004; 101: 12792-12797.
48. Cioce M, Lamond AI,. Cajal bodies: a long history of discovery. Annu Rev Cell Dev Biol 2005; 21: 105-131.
49. Venteicher AS, Abreu EB, Meng Z, et al. A human telomerase holoenzyme protein required for cajal body localization and telomere synthesis. Science 2009; 323: 644-8.